Eric H. Bjerkholt
Overview
Eric H. Bjerkholt received an average of $3M in total compensation, including $372K in salary, at Aimmune Therapeutics from 2017 to 2019. Eric Bjerkholt also received an average of $702K at Sunesis Pharmaceuticals from 2006 to 2017.
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2012
- 2011
- 2010
Aimmune TherapeuticsChief Financial Officer
Aimmune TherapeuticsChief Financial Officer
Sunesis PharmaceuticalsFormer Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Aimmune TherapeuticsChief Financial Officer
Sunesis PharmaceuticalsFormer Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Sunesis PharmaceuticalsExecutive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Sunesis PharmaceuticalsExecutive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Sunesis PharmaceuticalsExecutive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Sunesis PharmaceuticalsExecutive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Sunesis PharmaceuticalsExecutive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
Source: SEC filings on April 9, 2020, April 10, 2019, April 25, 2018, April 11, 2018, April 20, 2017, April 25, 2013, April 21, 2011, April 28, 2010, and April 27, 2007.
Related executives
We found 22 more executives who work or worked at Aimmune Therapeutics and Sunesis Pharmaceuticals.
Ivor Royston
Sunesis Pharmaceuticals
Chief Executive Officer
Lisa Rojkjaer
Sunesis Pharmaceuticals
Chief Medical Officer
Daniel Chevallard
Sunesis Pharmaceuticals
Chief Financial Officer
Par Hyare
Sunesis Pharmaceuticals
Chief Executive Officer
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
Andrew Oxtoby
Aimmune Therapeutics
Chief Commercial Officer
Douglas Sheehy
Aimmune Therapeutics
General Counsel
Daniel Adelman
Aimmune Therapeutics